UroGen Pharma Ltd. (URGN) experienced a significant after-hours surge of 7.78% on Monday. The biotech company's stock moved sharply higher following the release of its quarterly and annual financial results alongside a major financing update.

The company reported a narrowed fourth-quarter net loss of $0.54 per share, a significant improvement from a loss of $0.80 per share in the same period a year earlier. Quarterly revenue jumped 54% year-over-year to $37.8 million. For the full fiscal year 2025, UroGen reported revenue of $109.8 million, representing 21% growth, driven by sales of its products JELMYTO and the recently FDA-approved ZUSDURI.

Investors also reacted positively to the company's announcement of a refinanced term loan agreement with Pharmakon Advisors for up to $250 million. The deal provides $200 million in immediate funding at a fixed 8.25% interest rate with repayment beginning in 2030, strengthening the company's balance sheet and extending its financial runway. Additionally, positive Phase 3 trial results for pipeline candidate UGN-103 and a maintained "Buy" rating from analysts contributed to the optimistic market sentiment.